Bayer announced on Wednesday that it will appoint Sebastian Guth, an in-house executive, as Chief Operating Officer (COO) of its pharmaceuticals division, with the aim of revitalizing the division's growth.

Sebastian Guth, who until now has headed the German group's US subsidiary, will remain based in the USA, reporting to Stefan Oelrich, the current President of Bayer's pharmaceuticals division.

To support him, Bayer Santé has decided to appoint Christine Roth, current head of its oncology subsidiary, to head a new entity dedicated to global marketing activities.

Copyright (c) 2024 CercleFinance.com. All rights reserved.